statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Grifols 2023 Annual Report on Form 20-F filed with the SEC Grifols 2023 Annual Report on Form 20-F filed with the SEC PR Newswire BARCELONA, Spain, April 19, 2024 BARCELONA, Spain, April 19, 2024...

Grifols 2023 Annual Report on Form 20-F filed with the SEC

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Grifols says all liabilitites disclosed in audited financial statements

Grifols' in vitro nucleic acid test detects four types of arboviruses, helping mitigate the risk of transfusion-transmitted infections Arboviruses are a growing emerging threat, with changes in...

Grifols Procleix ArboPlex Assay  Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Screening

Grifols simplifies financial presentation, limits non-recurring items

If you're interested in broad exposure to the Healthcare - Biotech segment of the equity market, look no further than the First Trust NYSE Arca Biotechnology ETF (FBT), a passively managed exchange...

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

NEW YORK, March 31, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Grifols S.A. ( Grifols or the Company ) (NASDAQ: GRFS). Such investors are advised to...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Grifols S.A. - GRFS

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages GRFS American Depositary Receipt Investors with Substantial Losses to Contact FirmSAN FRANCISCO, March 29, 2024 (GLOBE NEWSWIRE) -- Hagens Berman...

Grifols S.A. (GRFS   ADR ADR Class B) Shares Decline Again After Gotham City Research Issues Another Critical Report   Hagens Berman

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Grifols S.A. - GRFS SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Grifols...

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages GRFS American Depositary Receipt Investors with Substantial Losses to Contact FirmSAN FRANCISCO, March 25, 2024 (GLOBE NEWSWIRE) -- Hagens Berman...

NEW YORK, March 23, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Grifols S.A. ( Grifols or the Company ) (NASDAQ: GRFS). Such investors are advised to...

Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.

Volume	896,472.00
52-Wk High	$12.15
52-Wk Low	$5.30

GRFS Grifols, SA

About

Feed

News

Sentiment

Earnings

Fundamentals